Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma

Sarah T. Wilkinson, Kristie A. Vanpatten, Diane R. Fernandez, Patrick Brunhoeber, Karl E. Garsha, Betty J. Glinsmann-Gibson, Thomas M. Grogan, Julie Teruya-Feldstein, Lisa M. Rimsza

Blood (2012) 119 (6): 1459–1467.

https://doi.org/10.1182/blood-2011-07-363820

Published: 2012

Journal Articles

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP

Lisa M. Rimsza, Michael L. LeBlanc, Joseph M. Unger, Thomas P. Miller, Thomas M. Grogan, Daniel O. Persky, Ralph R. Martel, Constantine M. Sabalos, Bruce Seligmann, Rita M. Braziel, Elias Campo, Andreas Rosenwald, Joseph M. Connors, Laurie H. Sehn, Nathalie Johnson, Randy D. Gascoyne

Blood (2008) 112 (8): 3425–3433.

https://doi.org/10.1182/blood-2008-02-137372

Published: 2008

Includes: Supplemental data

Journal Articles

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

Blood (2007) 109 (11): 4599–4606.

https://doi.org/10.1182/blood-2006-08-039859

Published: 2007

Journal Articles

Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).

Robin A. Roberts, BS, Lisa M. Rimsza, M.D., Louis Staudt, M.D.Ph.D., Andreas Rosenwald, M.D., Wing-Chung Chan, M.D., Sandeep Dave, M.D., Randy D. Gascoyne, M.D., Joseph M. Connors, M.D., Erlend B. Smeland, M.D.Ph.D., H.K. Muller-Hermelink, M.D., Elias Campo, M.D., Elaine S. Jaffe, M.D., Wyndham Wilson, M.D., Bruce K. Tan, M.D., Richard I. Fisher, M.D., Thomas M. Grogan, M.D., Thomas P. Miller, MD

Blood (2006) 108 (11): 809.

https://doi.org/10.1182/blood.V108.11.809.809

Published: 2006

Journal Articles

Induced Major Histocompatibility Class II (MHCII) Expression Does Not Alter Chemosensitivity, Radiosensitivity, Redox Potential, or Proliferation Rate in a CIITA-Transfected Diffuse Large B Cell Lymphoma (DLBCL) Cell Line.

Betty J. Glinsmann-Gibson, MS, Kelly A. Cycon, Shawn P. Murphy, Ph.D., Thomas P. Miller, M.D., Thomas M. Grogan, M.D., Margaret E. Tome, Ph.D., Margaret M. Briehl, Ph.D., Lisa M. Rimsza, MD

Blood (2006) 108 (11): 2040.

https://doi.org/10.1182/blood.V108.11.2040.2040

Published: 2006

Journal Articles

Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival

Robin A. Roberts, George Wright, Andreas R. Rosenwald, Marina A. Jaramillo, Thomas M. Grogan, Thomas P. Miller, Yvette Frutiger, Wing C. Chan, Randy D. Gascoyne, German Ott, H. Konrad Muller-Hermelink, Louis M. Staudt, Lisa M. Rimsza

Blood (2006) 108 (1): 311–318.

https://doi.org/10.1182/blood-2005-11-4742

Published: 2006

Journal Articles

Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions

Blood (2006) 107 (3): 1101–1107.

https://doi.org/10.1182/blood-2005-04-1510

Published: 2006

Journal Articles

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

Margaret E. Tome, David B. F. Johnson, Lisa M. Rimsza, Robin A. Roberts, Thomas M. Grogan, Thomas P. Miller, Larry W. Oberley, Margaret M. Briehl

Blood (2005) 106 (10): 3594–3601.

https://doi.org/10.1182/blood-2005-02-0487

Published: 2005

Journal Articles

Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction

Blood (2005) 106 (9): 3183–3190.

https://doi.org/10.1182/blood-2005-04-1399

Published: 2005

Includes: Supplemental data

Journal Articles

High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA.

Blood (2004) 104 (11): 697.

https://doi.org/10.1182/blood.V104.11.697.697

Published: 2004

Journal Articles

Gene Expression Profiling, Frozen and Paraffin Section Immunohistochemistry, and In Situ Hybridization for Determination of Monoclonality in Diffuse Large B-Cell Lymphoma.

Matthew W. Andres, DO, Robin A. Roberts, BS, Debbie J. Mustacich, PhD, Randy D. Gascoyne, MD, Deborah A. Fuchs, MD, Michael X. Wang, MD, Rita M. Braziel, MD, Wing C. Chan, MD, Thomas M. Grogan, MD, Lisa M. Rimsza, MD

Blood (2004) 104 (11): 4553.

https://doi.org/10.1182/blood.V104.11.4553.4553

Published: 2004

Journal Articles

Fc γ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800).

David G. Maloney, MD, PhD, Barbara Pender-Smith, MS, Joseph M. Unger, MS, Rita M. Braziel, MD, Jerald Radich, MD, Oliver W. Press, MD, PhD, Thomas P. Miller, MD, Thomas M. Grogan, MD, Michael LeBlanc, PhD, Richard I. Fisher, MD

Blood (2004) 104 (11): 589.

https://doi.org/10.1182/blood.V104.11.589.589

Published: 2004

Journal Articles

Gene Expression Profiling of Peripheral T-Cell Lymphoma (PTCL, NOS) and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL).

Daruka Mahadevan, MD/PhD, Catherine Spier, MD, Kimiko Della Croce, BS, Susan Miller, PhD, Benjamin George, Christopher J. Riley, BS, Stephen Warner, BS, Thomas M. Grogan, MD, Thomas P. Miller, MD.

Blood (2004) 104 (11): 2277.

https://doi.org/10.1182/blood.V104.11.2277.2277

Published: 2004

Journal Articles

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project

Lisa M. Rimsza, Robin A. Roberts, Thomas P. Miller, Joseph M. Unger, Michael LeBlanc, Rita M. Braziel, Dennis D. Weisenberger, Wing C. Chan, H. Konrad Muller-Hermelink, Elaine S. Jaffe, Randy D. Gascoyne, Elias Campo, Deborah A. Fuchs, Catherine M. Spier, Richard I. Fisher, Jan Delabie, Andreas Rosenwald, Louis M. Staudt, Thomas M. Grogan

Blood (2004) 103 (11): 4251–4258.

https://doi.org/10.1182/blood-2003-07-2365

Published: 2004

Journal Articles

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

James R. Berenson, John J. Crowley, Thomas M. Grogan, Jeffrey Zangmeister, Adrienne D. Briggs, Glenn M. Mills, Bart Barlogie, Sydney E. Salmon

Blood (2002) 99 (9): 3163–3168.

https://doi.org/10.1182/blood.V99.9.3163

Published: 2002

Journal Articles

The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features

Rita M. Braziel, Daniel A. Arber, Marilyn L. Slovak, Margaret L. Gulley, Catherine Spier, Carl Kjeldsberg, Joseph Unger, Thomas P. Miller, Raymond Tubbs, Catherine Leith, Richard I. Fisher, Thomas M. Grogan

Blood (2001) 97 (12): 3713–3720.

https://doi.org/10.1182/blood.V97.12.3713

Published: 2001

Journal Articles

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes

William T. Bellamy, Lynne Richter, Davuud Sirjani, Concepcion Roxas, Betty Glinsmann-Gibson, Yvette Frutiger, Thomas M. Grogan, Alan F. List

Blood (2001) 97 (5): 1427–1434.

https://doi.org/10.1182/blood.V97.5.1427

Published: 2001

NARROW

Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).

Induced Major Histocompatibility Class II (MHCII) Expression Does Not Alter Chemosensitivity, Radiosensitivity, Redox Potential, or Proliferation Rate in a CIITA-Transfected Diffuse Large B Cell Lymphoma (DLBCL) Cell Line.

Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival

Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction

High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA.

Gene Expression Profiling, Frozen and Paraffin Section Immunohistochemistry, and In Situ Hybridization for Determination of Monoclonality in Diffuse Large B-Cell Lymphoma.

Fc γ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800).

Gene Expression Profiling of Peripheral T-Cell Lymphoma (PTCL, NOS) and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL).

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only